Publications by authors named "Y Tsubakihara"
Background: The Greenhouse gas Observations of Biospheric and Local Emissions from the Upper sky (GOBLEU) is a new joint project by Japan Aerospace Exploration Agency (JAXA) and ANA HOLDING INC. (ANAHD), which operates ANA flights. GOBLEU aims to visualizes our climate mitigation effort progress in support of subnational climate mitigation by collecting greenhouse gas (GHG) data as well as relevant data for emissions (nitrous dioxide, NO) and removals (Solar-Induced Fluorescence, SIF) from regular passenger flights.
View Article and Find Full Text PDFBACKGROUND: Difelikefalin, a peripherally specific selective agonist of kappa opioid receptors, has been approved for the treatment of pruritus in hemodialysis patients in the United States. However, there is limited evidence for postdialysis intravenous use in non-U.S.
View Article and Find Full Text PDFHigher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial.
Clin Exp Nephrol
September 2023
Background: In the primary analysis of the PREDICT trial, a higher hemoglobin target (11-13 g/dl) with darbepoetin alfa did not improve renal outcomes compared with a lower hemoglobin target (9-11 g/dl) in advanced chronic kidney disease (CKD) without diabetes. Prespecified secondary analyses were performed to further study the effects of targeting higher hemoglobin levels on renal outcomes.
Methods: Patients with an estimated glomerular filtration rate (eGFR) 8-20 ml/min/1.
Article Synopsis
- A study was conducted involving 1,980 adults with non-dialysis-dependent chronic kidney disease (ND-CKD) to evaluate the effectiveness of erythropoiesis-stimulating agents (ESAs) and their impact on renal and cardiovascular outcomes.
- The research found that poor response to erythropoiesis-stimulating agents, indicated by a specific formula (dose of darbepoetin alfa divided by hemoglobin level), was significantly linked to a higher risk of progression in kidney disease and cardiovascular events.
- The study recommends using a cut-off value of 5.2 for this formula to identify patients at risk, emphasizing the need to investigate underlying causes of poor response in these individuals.
Importance: Patients with pruritus receiving hemodialysis frequently experience oppressive physical and psychiatric symptoms that directly affect their quality of life and increase mortality. However, treatment options are limited.
Objective: To determine the clinically recommended dose of difelikefalin, a κ-opioid receptor agonist, based on the efficacy, dose response, safety, and pharmacokinetics.